BTAX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BTAX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biostax's revenue for the three months ended in Jun. 2024 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil. Biostax's Revenue per Share for the three months ended in Jun. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, Biostax's highest 3-Year average Revenue per Share Growth Rate was 36.20% per year. The lowest was 36.20% per year. And the median was 36.20% per year.
The historical data trend for Biostax's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biostax Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Biostax Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Biostax's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Biostax's Revenue distribution charts can be found below:
* The bar in red indicates where Biostax's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biostax (OTCPK:BTAX) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Biostax's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Glen A Farmer | officer: Chief Financial Officer | 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876 |
H. Louis Salomonsky Jr. Revocable Trust | 10 percent owner | 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792 |
Henry Louis Salomonsky | director, 10 percent owner | 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792 |
Kelly O'brien Wilson | 10 percent owner, officer: COO and ICEO and IP | 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792 |
James Norman Curley | other: Member of 10% owner group | 410 DAHLIA AVE, CORONA DEL MAR CA 92625 |
Empower Insurance Corp Ltd | other: Member of 10% owner group | 1254 LEEWARD HIGHWAY, 4 CARIBBEAN PLACE, PROVIDENCIALES W7 TKCA1ZZ |
Global Reverb Corp | 10 percent owner, other: Member of 10% owner group | 100 S EOLA DR, UNIT 1703, ORLANDO FL 32801 |
Paul Puskadi | other: Member of 10% owner group | 2020 TIGERTAIL BLVD, 7A, DANIA BEACH FL 33004 |
Deane Rhodes | other: Member of 10% owner group | 9200 HALSEY CIRCLE NE, TUSCALOOSA AL 35406 |
Roger Dale Bozarth | other: Member of 10% owner group | 9028 GREAT HERON CIR, ORLANDO FL 32836 |
Joel Yanowitz | other: Member of 10% owner group | 100 TAMAL PLZ, SUITE 106, CORTE MADERA CA 94925 |
Rogoff Family Trust Dtd | other: Member of 10% owner group | 20701 N SCOTTSDALE DR, ST 107-501, SCOTTSDALE AZ 85255 |
George Sasko | other: Member of 10% owner group | 515 WESTCHESTER DR, STE D, CAMPBELL CA 95008 |
Raster Investments, Inc | other: Member of 10% owner group | 2384 ORCHARD CREST BLVD, MANASQUAN NJ 08736 |
Robert Jackman Dailey | other: Member of 10% owner group | 401 FIRST STREET, LOS ALTOS CA 94022 |
From GuruFocus
By Marketwired Marketwired • 06-05-2018
By Marketwired Marketwired • 06-05-2018
By Marketwired Marketwired • 09-06-2018
By Marketwired Marketwired • 04-26-2018
By Marketwired Marketwired • 01-09-2019
By PRNewswire PRNewswire • 08-21-2020
By Marketwired Marketwired • 03-26-2018
By [email protected] [email protected] • 09-17-2019
By Marketwired Marketwired • 09-23-2019
By Marketwired Marketwired • 10-22-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.